Clinical and experimental nephrology
-
Clin. Exp. Nephrol. · Jun 2015
Underestimating chronic kidney disease by urine dipstick without serum creatinine as a screening tool in the general Japanese population.
It is not known if urine dipstick alone can identify chronic kidney disease (CKD) in the general Japanese population. ⋯ This study showed that a considerable population of CKD might be overlooked when only dipstick proteinuria is assessed for CKD screening. Hence, we strongly recommend that both urinalysis and serum creatinine measurement should be a part of the nationwide CKD screening system.
-
Clin. Exp. Nephrol. · Jun 2015
Hypoadiponectinemia correlates with arterial stiffness in kidney transplantation patients.
Adiponectin is a fat-derived hormone produced and secreted exclusively by adipocytes that have anti-atherosclerotic effects. The aim of this study was to evaluate the relationship between fasting serum adiponectin levels and arterial stiffness among kidney transplant (KT) patients. ⋯ Serum fasting adiponectin level was inversely associated with arterial stiffness among KT patients.
-
Clin. Exp. Nephrol. · Jun 2015
Serum galectin-3 levels were associated with proteinuria in patients with Familial Mediterranean Fever.
The most common and pernicious complication of Familial Mediterranean fever (FMF) is renal amyloidosis, usually affecting the kidneys, leading to end-stage renal failure. FMF-related renal amyloidosis needed to be diagnosed early. Optimal colchicine dose is effective in preventing and reversing renal amyloidosis. Galectin-3, profibrotic mediator, has regulatory functions in inflammation, fibrosis and tumorigenesis. Galectin-3 is a strong prognostic marker for heart failure. Galectin-3 plays role in diabetic nephropathy and chronic kidney disease. The aim of the study is to investigate whether galectin-3 is related to proteinuria and amyloidosis in FMF. ⋯ Galectin-3 is associated with proteinuria and renal amyloidosis in FMF. Galectin-3 may play role in pathogenesis of amyloidosis.
-
Clin. Exp. Nephrol. · Dec 2014
Randomized Controlled Trial Multicenter Study Comparative StudyEffects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout. The objective of this study was to evaluate the efficacy and safety of topiroxostat in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ⋯ Topiroxostat 160 mg effectively reduced the serum urate level in the hyperuricemic stage 3 chronic kidney disease patients with or without gout.
-
Clin. Exp. Nephrol. · Oct 2014
Comparative StudyComparison of kidney disease: improving global outcomes and acute kidney injury network criteria for assessing patients in intensive care units.
The Kidney Disease: Improving Global Outcomes (KDIGO) group proposed to adopt the 48-h time window for the 0.3 mg/dL rise in serum creatinine (sCr) proposed by the Acute Kidney Injury Network (AKIN) group as a modification to the original risk, injury, failure, loss, and end-stage renal disease criteria, keeping the 7-day window for the 50 % increase in sCr from baseline. The present study evaluates the prevalence of acute kidney injury (AKI) and the accuracy of predicting mortality based on the KDIGO and AKIN criteria. ⋯ The KDIGO criteria have improved sensitivity without compromising specificity for AKI and might predict mortality at least as well as the AKIN criteria.